This looks pretty damn good. Not sure if I am reading this right but it appears they can not find my cancer any more and my Prostate has shrunk from 150cc to 74cc.
"PI-RADS 2 - Low probability of cancer (Clinically significant cancer is unlikely to be present)" My MRI in July 21 was rated PI-RADS -5.
It seems at the very least that the cancer has been dealt a severe set back, but is this normal after 7 months on ADT?
What say you more experienced brothers?
Study Result
Impression
CONCLUSION:
1. The prior noted enhancing lesion with restricted diffusion along the peripheral zone at the apex of the left lobe of the gland is no longer noted.
2. The prior noted adenopathy within the left ischial rectal fossa has resolved. No evidence of adenopathy noted on the current exam.
3. Multiple BPH nodules are seen throughout both lobes of the prostate. No focal regions of restricted diffusion or abnormal enhancement identified. This is considered a PI rads category 2 study.
PI-RADS 1 - Very low probability of cancer (Clinically significant cancer is highly unlikely to be present)
PI-RADS 2 - Low probability of cancer (Clinically significant cancer is unlikely to be present)
PI-RADS 3 - Intermediate probability of cancer (The presence of clinically significant cancer is equivocal)
PI-RADS 4 - High probability of cancer (Clinically significant cancer is likely to be present)
PI-RADS 5 - Very high probability of cancer (Clinically significant cancer is highly likely to be present)
Cancer Imaging: 2016.
Dictated by (CST): Malik, Amaar, DO on 4/20/2022 at 1:41 PM
Finalized by (CST): Malik, Amaar, DO on 4/20/2022 at 1:56 PM
Narrative
PROCEDURE: MRI PROSTATE (W+WO)(CPT=72197)
INDICATIONS: 73-year-old male with history of biopsy proven prostate cancer
COMPARISON: EDWARD , MR, MRI PROSTATE (W+WO)(CPT=72197), 7/27/2021, 2:03 PM.
TECHNIQUE: 3T. Body coil. Multiplanar T1, T2 weighted, 3D T2 weighted imaging sequences. Multi b value Diffusion weighted sequences. Dynamic post infusion sequences after the administration of 16 cc IV gadolinium based contrast.
PATIENT STATED HISTORY:(As transcribed by Technologist)
CONTRAST USED: 16 cc of Dotarem, IV.
PSA HISTORY: Biopsy proven prostate cancer, with biopsy being performed in 2021.
FINDINGS:
PSA VALUE: 0.03 ng/mL obtained on 4/15/2022
PROSTATE VOLUME: 74 cc
(L x W x AP) x 0.52
RIGHT LOBE: There are multiple BPH nodules seen throughout the transitional zone. No peripheral zone lesions noted. No foci of restricted diffusion or abnormal enhancement.
LEFT LOBE: Multiple BPH nodules are seen throughout the transitional zone. The prior noted enhancing lesion with restricted diffusion along the apex of the gland posteriorly involving the peripheral zone is not discretely seen on
the current study. No foci of restricted diffusion or abnormal enhancement noted.
SEMINAL VESICLES: Symmetric and unremarkable.
ADENOPATHY: The prior noted adenopathy within the left ischial rectal fossa has resolved. No foci of adenopathy noted.
VISUALIZED PELVIC BONE MARROW: Prior noted nonspecific ovoid foci of decreased T2 bone marrow signal involving the right proximal femoral metaphysis and left femoral head are stable/unchanged.
Component Results
There is no component information for this result.
General Information
Ordered by PHYSICIAN NONSTAFF
Collected on 04/20/2022 1:56 PM
Resulted on 04/20/2022 1:56 PM
Result Status: Final result
This test result has been released by an automatic process.